Peptides最新文献

筛选
英文 中文
Potential role of integrin αV as irisin receptor and advances in research 整合素αV作为鸢尾素受体的潜在作用及研究进展。
IF 2.9 4区 医学
Peptides Pub Date : 2025-11-01 Epub Date: 2025-09-13 DOI: 10.1016/j.peptides.2025.171439
Zina Bai , Zelin Chen , Tongxinwei Sun , Cuiqing Ma , Aihong Meng
{"title":"Potential role of integrin αV as irisin receptor and advances in research","authors":"Zina Bai ,&nbsp;Zelin Chen ,&nbsp;Tongxinwei Sun ,&nbsp;Cuiqing Ma ,&nbsp;Aihong Meng","doi":"10.1016/j.peptides.2025.171439","DOIUrl":"10.1016/j.peptides.2025.171439","url":null,"abstract":"<div><div>Irisin, initially described as a myokine, is widely distributed throughout the body and is released during physical exercise. It exerts beneficial effects on multiple tissues and, organs, and in systemic diseases, including neurological, metabolic, cardiovascular, pulmonary, and musculoskeletal disorders. Recent studies have highlighted the role of irisin receptors in various disease models and cell types, identifying integrin αV, particularly integrin αVβ5, as a key irisin-binding receptor. This review summarizes the current findings on irisin receptor biology and elucidates the mechanisms by which irisin mediates its effects via these receptors in various diseases. We propose that integrin αVβ5 receptors may represent promising therapeutic target for the treatment of diseases associated with exercise-induced irisin, offering a novel perspective for the alleviation of systemic diseases through exercise and rehabilitation.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"193 ","pages":"Article 171439"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salusin-α preserves glomerular endothelial barrier function in hypertension via YAP/ZO-1 signaling pathway Salusin-α通过YAP/ZO-1信号通路保护高血压患者肾小球内皮屏障功能
IF 2.9 4区 医学
Peptides Pub Date : 2025-11-01 Epub Date: 2025-09-17 DOI: 10.1016/j.peptides.2025.171441
Lang Li , Huan Wang , ChunYu Zhao
{"title":"Salusin-α preserves glomerular endothelial barrier function in hypertension via YAP/ZO-1 signaling pathway","authors":"Lang Li ,&nbsp;Huan Wang ,&nbsp;ChunYu Zhao","doi":"10.1016/j.peptides.2025.171441","DOIUrl":"10.1016/j.peptides.2025.171441","url":null,"abstract":"<div><div>Hypertensive nephropathy (HN) is a leading cause of end-stage renal disease, driven by glomerular endothelial barrier dysfunction, inflammation, and tight junction impairment. Salusin-α, an endogenous bioactive peptide with cardiovascular protective properties, has emerged as a potential regulator of renal homeostasis, but its role in hypertensive renal injury remains unclear. This study investigated the protective effects of Salusin-α on glomerular endothelial barrier function and its underlying mechanism via the YAP/ZO-1 signaling pathway. Male C57BL/6 mice were randomized into control, angiotensin II/high-salt (ANG/HS)-induced hypertensive, and ANG/HS + Salusin-α (1 or 2 μg/kg) groups. Hypertensive mice exhibited reduced serum and renal Salusin-α levels (∼43 % and ∼55 %, respectively), increased renal inflammation (IL-1β, TNF-α, MCP-1 upregulated 2.6–3.1-fold), albuminuria (82.6 vs. 19.3 μg/day in controls), and ZO-1 downregulation (∼51 %). Salusin-α treatment dose-dependently restored ZO-1 expression (95 % of control levels at 2 μg/kg) and reduced albuminuria (∼48 %). In human renal glomerular endothelial cells (HRGECs), Salusin-α (10 nM) mitigated ANG/HS-induced barrier dysfunction (FITC-dextran flux reduced from 41.3 % to 19.6 %; TEER restored from 105.2 to 169.8 Ω·cm²) by inhibiting YAP nuclear translocation (∼52 % reduction) and preserving ZO-1. Critically, YAP overexpression abolished Salusin-α’s protective effects on ZO-1 and barrier integrity. These findings demonstrate that Salusin-α alleviates hypertensive renal injury by suppressing YAP-mediated ZO-1 degradation, thereby preserving glomerular endothelial barrier function and reducing inflammation. The study identifies Salusin-α as a novel therapeutic candidate targeting the YAP/ZO-1 axis in hypertensive nephropathy.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"193 ","pages":"Article 171441"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Duramycin: Exploring the therapeutic frontier of a unique lantibiotic 杜拉霉素:探索一种独特抗生素的治疗前沿
IF 2.9 4区 医学
Peptides Pub Date : 2025-11-01 Epub Date: 2025-10-11 DOI: 10.1016/j.peptides.2025.171447
Meng Yuan , Shuaiming Bao , Kejun Wu , Zixin Deng , Jiangtao Gao
{"title":"Duramycin: Exploring the therapeutic frontier of a unique lantibiotic","authors":"Meng Yuan ,&nbsp;Shuaiming Bao ,&nbsp;Kejun Wu ,&nbsp;Zixin Deng ,&nbsp;Jiangtao Gao","doi":"10.1016/j.peptides.2025.171447","DOIUrl":"10.1016/j.peptides.2025.171447","url":null,"abstract":"<div><div>This review evaluates duramycin, a lantibiotic antimicrobial peptide, focusing on its biochemical properties, biosynthetic mechanisms, structural characteristics, and therapeutic applications. We examine the critical role of lanthionine and methyllanthionine in antimicrobial efficacy and trace duramycin's development trajectory. Molecular analysis of duramycin highlights the significance of post-translational modifications and leader peptide interactions in its functionality. The peptide's mechanism of action, which involves disrupting membrane integrity through phosphatidylethanolamine binding, forms the foundation of its antimicrobial activity. We assess duramycin's clinical progress, particularly its advancement to Phase II trials for cystic fibrosis therapy, and evaluate its potential against viral infections. The review addresses challenges in production, resistance development, and clinical delivery while exploring emerging applications in cancer treatment, diagnostics, and molecular probes for studying membrane dynamics. We conclude by examining future directions for lantibiotic engineering and the broader implications of duramycin research for antimicrobial therapy and biomedicine.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"193 ","pages":"Article 171447"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145268935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Substitution of a proline residue in the frog skin host-defense peptide, figainin-2PL by D-lysine generates an analog with potent activity against antibiotic-resistant ESKAPE pathogens 用d -赖氨酸取代青蛙皮肤宿主防御肽中的脯氨酸残基,可以产生一种对耐抗生素ESKAPE病原体具有有效活性的类似物。
IF 2.8 4区 医学
Peptides Pub Date : 2025-10-01 Epub Date: 2025-07-12 DOI: 10.1016/j.peptides.2025.171430
Laure Guilhaudis , Taylor S. Cunning , Jack J. Delaney , Nigel G. Ternan , Milena Mechkarska , Samir Attoub , J. Michael Conlon
{"title":"Substitution of a proline residue in the frog skin host-defense peptide, figainin-2PL by D-lysine generates an analog with potent activity against antibiotic-resistant ESKAPE pathogens","authors":"Laure Guilhaudis ,&nbsp;Taylor S. Cunning ,&nbsp;Jack J. Delaney ,&nbsp;Nigel G. Ternan ,&nbsp;Milena Mechkarska ,&nbsp;Samir Attoub ,&nbsp;J. Michael Conlon","doi":"10.1016/j.peptides.2025.171430","DOIUrl":"10.1016/j.peptides.2025.171430","url":null,"abstract":"<div><div>Figainin-2PL (FLGTVLKLGKAIAKTVVPMLTNAMQPKQ.NH<sub>2</sub>) is active against a range of antibiotic-resistant bacteria as well as human tumor-derived cells. The study aimed to determine the effects of a proline-substitution on the biological potency of the peptide. Secondary structure predictions indicate that figainin-2PL can adopt a helix-turn-helix conformation in membrane-mimetic environments. Circular dichroism spectra are consistent with these predictions. Replacement of the Pro<sup>18</sup> residue by either L-Ala, L-Lys or D-Lys increased the extent and stability of the helical domains. All substitutions increased cytotoxic activity against a range of human tumor-derived cells (between 1.5- and 3-fold) but major (between 4- and 10-fold) increases in hemolytic activity against mouse erythrocytes were also observed. While the substitutions Pro<sup>18</sup> → L-Ala and Pro<sup>18</sup> → L-Ala produced only minor and inconsistent changes in antibacterial activity, the [P18k] analog displayed a 2- to 4-fold greater (MIC and MBC in the range 1–8 µM) against the ESKAPE pathogens <em>Enterococcus faecalis</em>, <em>Enterococcus faecium, Klebsiella pneumoniae</em> and <em>Pseudomonas aeruginosa</em> compared with figainin-2PL and the peptide retained high potency against <em>Acinetobacter baumannii</em>, <em>Escherichia coli, Staphylococcus aureus</em> and <em>Clostridium difficile</em> (MIC and MBC = 2 µM). Consequently, the [P18k] peptide shows therapeutic potential for development into a broad-spectrum, topical antimicrobial agent.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"192 ","pages":"Article 171430"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation Between decreased mixed venous oxygen saturation and increased B-type natriuretic peptides independent of hemodynamics in pre-heart failure/heart failure patients 心衰前期/心衰患者混合静脉氧饱和度降低与独立于血流动力学的b型利钠肽增加的相关性
IF 2.8 4区 医学
Peptides Pub Date : 2025-10-01 Epub Date: 2025-07-22 DOI: 10.1016/j.peptides.2025.171433
Yusuke Kashiwagi , Tomohisa Nagoshi , Ryuji Funaki , Yuto Mashitani , Satoshi Ito , Kazuo Ogawa , Makoto Kawai , Michifumi Tokuda , Michihiro Yoshimura
{"title":"Correlation Between decreased mixed venous oxygen saturation and increased B-type natriuretic peptides independent of hemodynamics in pre-heart failure/heart failure patients","authors":"Yusuke Kashiwagi ,&nbsp;Tomohisa Nagoshi ,&nbsp;Ryuji Funaki ,&nbsp;Yuto Mashitani ,&nbsp;Satoshi Ito ,&nbsp;Kazuo Ogawa ,&nbsp;Makoto Kawai ,&nbsp;Michifumi Tokuda ,&nbsp;Michihiro Yoshimura","doi":"10.1016/j.peptides.2025.171433","DOIUrl":"10.1016/j.peptides.2025.171433","url":null,"abstract":"<div><div>Previous studies have shown that natriuretic peptides (NPs) respond to hypoxia. Mixed venous oxygen saturation (SvO₂) reflects the oxygen balance and may indicate pulmonary hypoxia. In this study, we investigated whether NPs are influenced by SvO₂ and whether this effect differs between A-type natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in heart failure patients, using structural equation modeling (SEM). We examined 179 patients with pre-heart failure/heart failure who underwent Swan-Ganz catheterization, and investigated the relationship between NP levels and various clinical parameters, including SvO₂. The path model showed that pulmonary artery wedge pressure (PAWP) and administration of angiotensin receptor-neprilysin inhibitor (ARNI) were significantly positively associated with ANP (PAWP: standardized regression coefficient [St. β] =0.281, P = 0.002; ARNI administration: St. β=0.396, P &lt; 0.001). PAWP and ischemic heart disease (IHD) were positively associated with BNP, whereas the estimated glomerular filtration rate (eGFR) and SvO₂ were negatively associated with BNP (PAWP: St. β =0.370, P &lt; 0.001; IHD: St. β =0.241, P &lt; 0.001; eGFR: St. β =-0.209, P = 0.003; SvO₂: St. β =-0.528, P &lt; 0.001). ANP was not associated with arterial oxygen saturation (SaO₂) or SvO₂, whereas BNP showed a negative relationship with SvO₂ but was not associated with SaO₂. Thus, an increased BNP, but not ANP, correlates strongly with decreased SvO₂, an indicator of hypoxia before pulmonary circulation, independent of hemodynamic indices.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"192 ","pages":"Article 171433"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FGF4 alleviates renal injury caused by ischemia-reperfusion(I/R) by inhibiting ferroptosis and pyroptosis FGF4通过抑制铁下垂和焦下垂减轻肾缺血再灌注(I/R)损伤
IF 2.9 4区 医学
Peptides Pub Date : 2025-10-01 Epub Date: 2025-08-19 DOI: 10.1016/j.peptides.2025.171438
Tong Ding , Pengjie Zhang , Kunying Wang , Peng Du , Bin Duan
{"title":"FGF4 alleviates renal injury caused by ischemia-reperfusion(I/R) by inhibiting ferroptosis and pyroptosis","authors":"Tong Ding ,&nbsp;Pengjie Zhang ,&nbsp;Kunying Wang ,&nbsp;Peng Du ,&nbsp;Bin Duan","doi":"10.1016/j.peptides.2025.171438","DOIUrl":"10.1016/j.peptides.2025.171438","url":null,"abstract":"<div><div>Renal ischemia-reperfusion injury can lead to severe renal function impairment, manifested by a significant increase in serum creatinine, renal tubular obstruction, and even necrosis, which can lead to acute renal failure. This injury can also trigger systemic inflammatory response syndrome and even lead to multiple organ dysfunction. It poses a serious threat to the life and health of patients, so it is urgent to find potential drugs for treatment. In our current work, we evaluated the effects of FGFs on kidney injury caused by ischemia-reperfusion. We first established a model of kidney cell injury caused by ischemia-reperfusion. The biological functions of FGFs were further evaluated through a series of biochemical techniques. The experimental data showed that, FGFs can effectively improve the damage of kidney cells caused by ischemia-reperfusion. FGFs can alleviate iron death and pyroptosis of kidney cells caused by ischemia-reperfusion. Further work showed that FGF4 also alleviated inflammation and oxidative stress damage caused by ischemia-reperfusion. Mechanism research also showed that FGFs effectively alleviated ischemia-reperfusion-induced kidney injury by activating AMPK-mediated signaling pathways. Furthermore, in vivo, we also found that FGF4 can effectively alleviate the kidney ischemia-reperfusion injury. This finding not only indicates the potential therapeutic prospects of FGF4 for ischemic diseases, but also provides a new pharmacological target for the treatment of renal ischemia-reperfusion injury.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"192 ","pages":"Article 171438"},"PeriodicalIF":2.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144895137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy 利拉鲁肽通过上调2型糖尿病心肌病患者的NRF2抑制铁下垂
IF 2.8 4区 医学
Peptides Pub Date : 2025-10-01 Epub Date: 2025-07-16 DOI: 10.1016/j.peptides.2025.171429
Xuepin Chen , Tianying Wang , Yan Gao , Guo an Wang , Jun Guan , Hongyan Dai
{"title":"Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy","authors":"Xuepin Chen ,&nbsp;Tianying Wang ,&nbsp;Yan Gao ,&nbsp;Guo an Wang ,&nbsp;Jun Guan ,&nbsp;Hongyan Dai","doi":"10.1016/j.peptides.2025.171429","DOIUrl":"10.1016/j.peptides.2025.171429","url":null,"abstract":"<div><div>Recent research indicates that inhibiting myocardial ferroptosis may help alleviate diabetic cardiomyopathy (DCM). Liraglutide (LIRA), a glucagon-like peptide-1 receptor agonist, has been shown to offer cardiovascular protective effects. Nevertheless, the specific role of LIRA and its relationship with myocardial ferroptosis in type 2 DCM is still not well understood. An <em>in vivo</em> model of type 2 diabetes mellitus (T2DM) was created using spontaneous diabetes Goto-Kakizaki (GK) rats. These rats received LIRA at a dose of 200 μg/kg/day through daily subcutaneous injections for 8 weeks. <em>In vitro</em> experiments involved treating H9C2 cells with different concentrations of glucose, LIRA, siRNA-Nrf2, Fer-1, or their combinations. The results demonstrated that LIRA enhanced glucose metabolism, improved cardiac remodeling and function, reduced lipid peroxidation, and mitigated myocardial ferroptosis in diabetic rats. Additionally, LIRA was found to increase the levels of proteins associated with ferroptosis, such as Cyto-NRF2, Nu-NRF2, PTGS2, FTH-1, and GPX4 in DCM. <em>In vitro</em>, high glucose levels intensified the production of lipid reactive oxygen species (ROS) and lipid peroxidation, diminished mitochondrial mass, and lowered the levels of ferroptosis-related proteins, ultimately triggering ferroptosis. Notably, these detrimental effects were mitigated by LIRA treatment. Overall, these results indicate that LIRA may serve as a valuable therapeutic option for addressing myocardial ferroptosis by promoting NRF2 expression in type 2 DCM.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"192 ","pages":"Article 171429"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ghrelin/GHSR-1a promotes angiogenesis after myocardial infarction through the glycolytic process Ghrelin/GHSR-1a通过糖酵解过程促进心肌梗死后血管生成
IF 2.8 4区 医学
Peptides Pub Date : 2025-10-01 Epub Date: 2025-07-22 DOI: 10.1016/j.peptides.2025.171434
Ming-Jie Yuan , Peng Zhong , Zhi-Xuan Shu , Li-Hua Zheng , Tao Liu , Song Dang
{"title":"Ghrelin/GHSR-1a promotes angiogenesis after myocardial infarction through the glycolytic process","authors":"Ming-Jie Yuan ,&nbsp;Peng Zhong ,&nbsp;Zhi-Xuan Shu ,&nbsp;Li-Hua Zheng ,&nbsp;Tao Liu ,&nbsp;Song Dang","doi":"10.1016/j.peptides.2025.171434","DOIUrl":"10.1016/j.peptides.2025.171434","url":null,"abstract":"<div><h3>Background</h3><div>Therapeutic angiogenesis has demonstrated efficacy in revascularizing ischemic heart tissue and reducing the progression of cardiac remodeling following myocardial infarction. Recent studies have highlighted the significance of the glycolytic process in maintaining endothelial cell function and cardiac homeostasis. However, the specific role of glycolysis in angiogenesis post-myocardial infarction remains poorly understood. This study aims to explore whether ghrelin/GHSR-1a promotes angiogenesis after myocardial infarction through glycolysis.</div></div><div><h3>Methods and results</h3><div>Myocardial infarction was induced in mice, and our experiments showed that GHSR-1a overexpression led to a significant increase in the density of α-SMA-positive vessels in the peri-infarct zones, compared to the MI group, at day 7 post-infarction. Furthermore, elevated FGF-21 levels were observed in the border zone of the infarcted area seven days post-acute myocardial infarction. We also identified a modified GHSR-1a/FGF-21 axis in cardiac endothelial cells, where GHSR-1a knockdown reduced the expression of both FGF-21 and AMPK. In vitro, ghrelin enhanced glycolytic activity by increasing the expression of glycolytic enzymes. Moreover, ghrelin significantly stimulated endothelial tube formation and enhanced cell viability; however, these effects were attenuated following FGF-21 knockdown.</div></div><div><h3>Conclusion</h3><div>Our findings demonstrate that ghrelin/GHSR-1a improves neovascularization and enhances glycolysis in cardiac endothelial cells by modulating FGF-21. These results lay the groundwork for further experimental and clinical investigations to explore pharmaceutical approaches for treating ischemic heart disease.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"192 ","pages":"Article 171434"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phoenixin-14 ameliorates acetic acid-induced ulcerative colitis in rats via antioxidant, anti-inflammatory and anti-apoptotic mechanisms 凤凰素-14通过抗氧化、抗炎和抗凋亡机制改善醋酸诱导的大鼠溃疡性结肠炎
IF 2.8 4区 医学
Peptides Pub Date : 2025-10-01 Epub Date: 2025-07-12 DOI: 10.1016/j.peptides.2025.171431
Hülya Buzcu , Meral Yüksel , Seda Kırmızıkan , Esra Çikler , Berna Karakoyun
{"title":"Phoenixin-14 ameliorates acetic acid-induced ulcerative colitis in rats via antioxidant, anti-inflammatory and anti-apoptotic mechanisms","authors":"Hülya Buzcu ,&nbsp;Meral Yüksel ,&nbsp;Seda Kırmızıkan ,&nbsp;Esra Çikler ,&nbsp;Berna Karakoyun","doi":"10.1016/j.peptides.2025.171431","DOIUrl":"10.1016/j.peptides.2025.171431","url":null,"abstract":"<div><div>Phoenixin (PNX), first discovered in the rat hypothalamus, was initially identified as a reproductive peptide. PNX-14 (14 amino acid isoform) has also been shown to function in cardiovascular regulation, neuroprotection, glucose metabolism, appetite, anxiety, and memory. We aimed to investigate the potential therapeutic role of PNX-14 in acetic acid (AA)-induced ulcerative colitis. Rats were given intrarectally 1 ml saline (control) or 5 % AA (colitis groups). The control group was treated intraperitoneally with saline, while the colitis groups were treated intraperitoneally with saline or PNX-14 (50 μg/kg/d) or gonadotrophin-releasing hormone (GnRH)-antagonist cetrorelix (CTX; 100 µg/kg/d) or CTX and PNX-14 or sulfasalazine as a positive control (100 mg/kg/d) instantly and once a day for 3 days following colitis induction. Colonic samples were evaluated histologically and biochemically [malondialdehyde (MDA), glutathione (GSH), myeloperoxidase (MPO), chemiluminescence (CL), pro-inflammatory cytokines (tumor necrosis factor-α, interferon-γ, interleukin (IL)-1β, IL-6, IL-8), caspase-3, and 8-hydroxy-2’-deoxyguanosine (8-OHdG) measurements] on the 3rd day. Elevated damage scores (macroscopic and microscopic), MPO, MDA, caspase-3, cytokines, and CL values, and decreased GSH levels of the colitis group were reversed by PNX-14 treatment (p &lt; 0.05–0.001). CTX or CTX plus PNX-14 reduced damage scores, caspase-3, 8-OHdG, cytokines, and CL values (p &lt; 0.05–0.001). Sulfasalazine treatment improved all parameters except MDA and GSH. PNX-14, which alleviates macroscopic, histological and biochemical parameters, can be considered as a potential therapeutic agent in ulcerative colitis with its anti-inflammatory, antioxidant and anti-apoptotic actions. Furthermore, despite its effects as an GnRH-antagonist, CTX has also revealed a similar beneficial role as PNX-14 in this ulcerative colitis model.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"192 ","pages":"Article 171431"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144634082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maximizing cost savings in heart failure management: The economic value of natriuretic peptide testing 心力衰竭管理的成本节约最大化:利钠肽检测的经济价值。
IF 2.8 4区 医学
Peptides Pub Date : 2025-10-01 Epub Date: 2025-07-11 DOI: 10.1016/j.peptides.2025.171428
Damien Gruson , Gaetano Caforio , Daniel D’Angela
{"title":"Maximizing cost savings in heart failure management: The economic value of natriuretic peptide testing","authors":"Damien Gruson ,&nbsp;Gaetano Caforio ,&nbsp;Daniel D’Angela","doi":"10.1016/j.peptides.2025.171428","DOIUrl":"10.1016/j.peptides.2025.171428","url":null,"abstract":"<div><div>Heart failure (HF) remains a significant global health challenge, requiring cost-effective strategies to optimize patient outcomes and resource allocation. Natriuretic peptide (NP) testing has demonstrated substantial clinical and economic value in HF diagnosis, risk stratification, and management. This article examines the international evidence supporting NP testing, highlighting its role in reducing hospitalizations, optimizing medication use, and lowering healthcare expenditures. Addressing disparities in access and reimbursement policies can further enhance its adoption and impact across healthcare systems.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"192 ","pages":"Article 171428"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书